Archive for February 2023

In clinical trial analysis, it’s assumed that participants are following the instructions for the investigational product. Unfortunately, the evidence suggests that this is far from reality. Recently, Kenneth Getz, Executive Director and Professor at the Tufts Center for the Study of Drug Development, shared in a Q&A session with AARDEX Group how digitalization is finally…

“Objective and granular” digital adherence measures could improve trial efficiency and allow for better-informed decisions on the efficacy and safety of new drug products. That’s according to the authors of a literature review that looked at more than 100 medicines approved by the European Medicines Agency (EMA) between 2010 and 2020. They found that while…

Greetings from the forefront of innovation in clinical trials. We’re thrilled to introduce you to the first edition of our medication adherence newsletter, Medication Monitoring Matters. Our focus? Empowering clinical trial sponsors like you to elevate the standard of care through improved adherence.  We’ll be sharing valuable insights, best practices, and the latest advancements in…

With the current push for increased diversity in research, the medical community has accepted the challenge to make trial populations more representative of those in clinical practice. Yet poor medication adherence, which clouds the view of how drugs work in the real world, continues to grow as a significant problem which ultimately jeopardizes drug development.  …

Seamless integration of adherence and research data protects participant safety and data quality, with no additional burden for clinical trial sites or participants Liege, Belgium- February 2, 2023: Adherence specialists AARDEX Group and remote research platform experts in the Clinpal team at Cambridge Cognition have teamed up to provide next-level adherence monitoring during hybrid and decentralized clinical trials (DCTs). Integrating AARDEX Group’s…